San Antonio Breast Cancer Symposium 2018: Was ist wichtig für unsere Patientinnen?

Seit 41 Jahren treffen sich in der ersten Dezemberhälfte Brustkrebsexperten in der texanischen Stadt San Antonio, unweit der Grenze zu Mexiko. Was 1977 als regionale, eintägige Konferenz begann, hat sich über die Jahre zu einem 5-tägigen Symposium mit etwa 7500 Teilnehmern aus mehr als 90 Ländern entwickelt und gilt als wichtigster Kongress dieser Art weltweit.

• Literatur

• 1 Emens LA, Loi S, Rugo HS. et al. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. SABCS 2018; Abstract GS1-04
• 2 Juric D, Ciruelos E, Rubovszky G. et al. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial. SABCS 2018; Abstract GS3-08
• 3 Spring LM, Fell G, Arfe A. et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. SABCS 2018; Abstract GS2-03
• 4 Geyer jr. CE, Huang C-S, Mano MS. et al. Phase III study of trastuzumab emtansine (T-DM1) vs. trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. SABCS 2018; Abstract GS1-10
• 5 von Minckwitz G, Huang CS, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2018;
• 6 Martín M, Barrios CH, Torrecillas L. et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS 2018; Abstract GS2-04
• 7 Masuda N, Lee SJ, Ohtani S. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376: 2147-2159
• 8 Morante Z, Ruiz R, De la Cruz-Ku G. et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer. SABCS 2018; Abstract GS2-05
• 9 Pivot X, Romieu G, Debled M. et al. PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. SABCS 2018; Abstract GS2-07
• 10 Earl HM, Cameron DA, Miles D. et al. PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer–Six versus twelve months. J Clin Oncol 2013; 31: TPS667
• 11 DeCensi A, Puntoni M, Guerrieri Gonzaga A. et al. A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ. SABCS 2018; Abstract GS3-01
• 12 Gray R. Early Breast Cancer Trialistsʼ Collaborative Group. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. SABCS 2018; Abstract GS3-03
• 13 Rutgers EJ, Donker M, Poncet C. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023). SABCS 2018; Abstract GS4-01
• 14 Munster P, Krischer J, Tamura R. et al. A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab. SABCS 2018; Abstract GS5-01
• 15 Thune I, Husøy A, Frydenberg H. et al. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial. SABCS 2018; Abstract GS5-02